System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Pierre Bigot is an expert in Urology at Centre Hospitalier Universitaire d'Angers (France). As of October 2026, ScienceLeadR ranks Pierre Bigot in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Urogenital Neoplasms. Pierre Bigot has authored 454 publications, the most recent in 2026, and is an investigator in 23 clinical trials, 12 of them ongoing. SLR score: 1,630 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Pierre Bigot Centre Hospitalier Universitaire d'Angers France
1 630 ScienceLeadR Reputation 1630

Unlock

Register Login
Network Map

Urology

Subspecialties: Oncology - Nephrology - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2007 - 2026
Source: PubMed

Association Française d'Urologie

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 454

Citations

Citations: 3 992 1st author: 53 Last author: 85 Unique author: 1

Main journals

Prog Urol 110
J Urol 50
World J Urol 32
EUR UROL SUPPL 30
Eur Urol 24

Best Journals

J Clin Oncol 11
Ann Oncol 5
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Biopsy and identification of risk factors for discordance in renal tumor: results from the BIRD study (UroCCR n°230).
PMID 42803961 — urology, neoplasms, biopsy, risk factors		World J Urol20260
Impact of resection bed management on postoperative outcomes after Robot-Assisted Partial Nephrectomy : a retrospective French Nationwide Study (UroCCR 215).
PMID 42758231 — urology, safety, hemostatics, neoplasms, nephrectomy, sutures		World J Urol20260
Low diagnostic yield of routine preoperative chest CT in patients undergoing partial nephrectomy: A national cohort study using UroCCR data (UroCCR n°216).
PMID 42719604 — margins of excision, cohort studies, nephrectomy, carcinoma, renal cell, diagnostic imaging, neoplasm metastasis		BJUI Compass20260
Durvalumab in Combination with Bacillus Calmette-Guérin Induction and Maintenance Therapy for Bacillus Calmette-Guérin-Naïve, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
PMID 42713893 — urinary bladder, urinary bladder neoplasms, urology, safety, muscles, neoplasms, bacillus, maintenance, therapeutics, non-muscle invasive bladder neoplasms		J Urol20260
Single-use vs. reusable flexible ureteroscopes: what do our patients prefer?
PMID 42700230 — ureteroscopes, urology		World J Urol20260

Clinical Studies 23

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 12
Phase 3 11

By status:

Recruiting 13
Active not recruiting 3
Completed 3
Unknown 3
Terminated 1

By type:

Interventional 17
Observational 6

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 3
multicentricup10 16

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

12 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CARE1 FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00 — cells, carcinoma, renal cell, therapeutics, carcinoma		Phase 3Recruiting2024
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK 6482 033)
2024-517136-21-00 — cells, neoplasms, kidney, carcinoma, renal cell, respect, kidney neoplasms, therapeutics, carcinoma		Phase 3Recruiting2025
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK 6482 034)
2024-516993-31-00 — cells, vascular endothelial growth factor a, neoplasms, double-blind method, kidney, carcinoma, renal cell, respect, kidney neoplasms, therapeutics, carcinoma		Phase 3Recruiting2026
Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post operative Febrile Urinary Tract Infections Prevention a Non inferiority Randomized Controlled Trial
NCT07463963 — urinary bladder, urinary bladder neoplasms, bacterial infections, urinary tract, neoplasms, urinary tract infections, infections		N/ARecruiting2026
FIRE Stones Impact of Furosemide on the residual fragment rate after flexible ureteroscopy for destruction of kidney stones with laser a controlled two parallel group multicenter trial with blinding evaluation
2022-502890-40-00 — kidney calculi, ureteroscopy, kidney, lasers, furosemide, fires, random allocation		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS